Syntara has completed full recruitment in its Phase 2 trial evaluating SNT-5055, in combination with ruxolitinib, treating the bone marrow cancer myelofibrosis.

  • Recruitment target achieved as 15th patient dosed
  • 12 patients exceed one month treatment and surpasses minimum threshold proposed in FDA discussions for safety evaluation.
  • No drug related dropouts & no serious adverse reactions
  • Syntara expects to announce interim data in December 2024, spurring additional regulatory discussions

Click here to read more